Hidradenitis suppurativa in psoriasis patients treated with secukinumab

Summary: Abstract Body: Secukinumab (cosentyx), a human monoclonal antibody targeting interleukin (IL)-17, has been demonstrated as an effective and relatively safe treatment for psoriasis by disrupting the IL-17-mediated inflammatory cascade responsible for psoriatic plaques. However, some case reports have suggested an association between secukinumab use in psoriasis patients and the onset of hidradenitis suppurativa (HS). We utilized the TrinetX database to investigate this potential link by analyzing data from 143 healthcare organizations. Patients who were treated with secukinumab after being diagnosed for psoriasis were compared to psoriasis patients who did not receive the treatment. Cohorts were propensity matched for age, sex, ethnicity, and race. Cohorts were matched a second time for additional obesity and tobacco use. Outcomes revealed an increased risk of HS in the secukinumab group (RR: 1.463, 95% CI: 1.143-1.874), corresponding to an absolute risk of 0.709% versus 0.463% in controls. After controlling for known HS risk factors, obesity and tobacco use, risk of secukinumab induced HS remained elevated (RR: 1.357, 95% CI: 1.065-1.728). Absolute risk ratios were 0.739% and 0.545% for secukinumab and control groups respectively. This study demonstrates a relationship between secukinumab treatment for psoriasis and induced HS. Although risk of HS during secukinumab treatment is relatively low, clinicians should be aware of these potential paradoxical symptoms and counsel patients if necessary. Dennis Chu¹, William Guo², Matthew Chen¹, James Briley² 1. Stony Brook University Renaissance School of Medicine, Stony Brook, NY, United States. 2. Stony Brook University Hospital, Stony Brook, NY, United States. Clinical Research: Epidemiology and Observational Research